


1 / 4 1

Fig. 1



2 / 4 1

Fig. 1




e**f****g**


Fig. 2

3 / 4 1

a

B6647

GAPDH

**b**

D7610

GAPDH

D7610

GAPDH

D7610

GAPDH

c

C4821


GAPDH

C4821

GAPDH





C4821

GAPDH




4 / 41

Fig. 2



5 / 4 1

Fig. 3



**Protein phosphatase 2C
catalytic domain
(68-506 aa)**

Fig. 4

6 / 4 1




Fig. 5

7 / 41




a**R1 AS1****ARHCL1****GAPDH****b****SNU-C4****LoVo****AS1****R1**

Fig. 6

8 / 41

A**ARHCL1-N****ARHCL1-C****B****GST- ARHCL1-N GST- ARHCL1-C**

(kDa)

0 2 4 (hr)

85 -

39.5 -

(kDa)

85 -

39.5 -

IB: anti-GST (AP biotech)

9 / 41

Fig. 7



A**B**

Fig. 8

1 0 / 4 1



A**B**

Fig. 9

11 / 41



a**b**

Fig. 10

12 / 41

SW480

SNU-C4

AS

R






Fig. 11

13 / 41

A**B**




1 4 / 4 1

Fig. 12



15 / 41

Fig. 13

A**B****C****CBB****IB: anti-His-tag Ab****CBB****IB: anti-His-tag Ab**

16 / 41

Fig. 14




A**B**

Fig. 15

17 / 41



IP: anti-FLAG
IB: anti-HA

Fig. 16

18 / 41



a**b**

Fig. 17

19 / 41




Fig. 18

20 / 41

SNU-C4

AS1

AS2

R1

R2







Fig. 19.

21 / 41

A**B**

22 / 41

Fig. 20

A**B**

pAS2-C20orf20


+

-

pACT2- BRD8

+

+

**C**

pFlag-C20orf20

-

+

+

+

pCMV-HA-BRD8

-

-

+

+

kDa 250-

150-

100-

75-

50-

37-

IP:anti-FLAG
IB: anti-HA




Fig. 21


23 / 41

a

mock pcDNAmyc/His-
CCPUCC1

b

pcDNA3.1myc/His-CCPUCC1



Anti-myc

DAPI

Merge

Fig. 22

24 / 41




a**b****c**

Fig. 23

25/41




A**B**


Fig. 24

26 / 41

A**HCT116****CCPUCC1-siRNA****control 2 3*****CCPUCC1
GAPDH****B****siRNA2****siRNA3****control**

27 / 41

Fig. 25.

anti-myc Ab anti-CCPUCC1 Ab

28 / 41

Fig. 26





Fig. 27


2 9 / 4 1

A


1/1000 dilution




1/500 dilution

**B**

1/1000 dilution




1/500 dilution




30 / 41

Fig. 28

A**B**

pcDNA -myc-CCPUCC1
pFlag-Clusterin

IB: anti-myc



pcDNA -myc-CCPUCC1
pFlag-Clusterin

IB: anti-FLAG








Fig. 29

3 1 / 4 1

A**B****C****D**

32 / 41

Fig. 30

a

mock pcDNAmyc/His-Ly6E

b

pcDNA3.1myc/His-Ly6E




Anti-myc

DAPI


Merge

33 / 41

Fig. 31.

a**b**

LoVo




S5


AS5

mock

LoVo

**c**

LoVo



LoVo




Fig. 32

3 4 / 4 1




Fig. 33

35 / 41

a

	mock	S4	AS4	S5	AS5
--	------	----	-----	----	-----

*Nkd1**GAPDH***b**

S4

AS4

mock

LoVo

S5

AS5


mock

SW480

c

LoVo


SW480



36 / 41

Fig. 34

a



b






Fig. 35

37 / 41




38 / 41

Fig. 36



39 / 41

Fig. 37



40 / 41

Fig. 38





Fig. 39.

41 / 41

AS1**AS2****AS3****AS4****AS5****REV1****REV2****REV3****REV4****REV5**